Retinoblastoma Treatment Market Report 2026

Retinoblastoma Treatment Market Overview

• Retinoblastoma Treatment market size has reached to $2.15 billion in 2025 • Expected to grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: Ophthalmic Treatment Demand Fuels Growth In Retinoblastoma Treatment Market • Market Trend: Advancement In Oncolytic Virotherapy Strengthens Growth Opportunities In The Retinoblastoma Treatment Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Retinoblastoma Treatment Market?

Retinoblastoma treatment refers to the medical interventions and therapies aimed at diagnosing, managing, and potentially curing retinoblastoma. Retinoblastoma is a rare form of eye cancer that primarily affects young children, typically before the age of five. The primary goal of retinoblastoma treatment is to eradicate or control the cancerous growths within the eye(s) while preserving vision and minimizing the risk of metastasis or recurrence. The main retinoblastoma treatment types are non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma is a rare form of cancer that typically affects children under the age of six. It has several type of treatments such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy and high-dose chemotherapy and stem cell transplant. It is used for both stages including intraocular retinoblastoma and extraocular retinoblastoma. It is frequently applied in hospitals, cancer institutes and others.

What Is The Retinoblastoma Treatment Market Growth Forecast?

The retinoblastoma treatment market size is expected to see steady growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing investments in pediatric oncology research, rising demand for minimally invasive therapies, expansion of precision medicine in oncology, growing focus on long-term quality of life outcomes, increasing adoption of advanced treatment delivery systems. Major trends in the forecast period include increasing adoption of targeted chemotherapy techniques, rising use of intra-arterial drug delivery, growing focus on vision-sparing treatments, expansion of multidisciplinary pediatric oncology care, enhanced early diagnosis and screening efforts.

Global Retinoblastoma Treatment Market Segmentation

1) By Type: Non-Hereditary Retinoblastoma, Hereditary Retinoblastoma 2) By Treatment Type: Surgery, Radiation Therapy, Laser Therapy (Photocoagulation), Cryotherapy, Thermotherapy, Chemotherapy, Ophthalmic Artery Infusion Chemotherapy, High-Dose Chemotherapy And Stem Cell Transplant 3) By Disease Stage: Intraocular Retinoblastoma, Extraocular Retinoblastoma 4) By Application: Hospitals, Cancer Institutes, Other Applications Subsegments: 1) By Non-Hereditary Retinoblastoma: Unilateral Non-Hereditary Retinoblastoma, Bilateral Non-Hereditary Retinoblastoma 2) By Hereditary Retinoblastoma: Bilateral Hereditary Retinoblastoma, Unilateral Hereditary Retinoblastoma

What Is The Driver Of The Retinoblastoma Treatment Market?

The increasing demand for ophthalmic treatment and surgeries is expected to propel the growth of the retinoblastoma treatment market going forward. Ophthalmic treatment and surgeries encompass medical interventions and procedures to diagnose, manage, and correct disorders and conditions affecting the eyes and visual system. Ophthalmic treatment and surgeries are increasing due to an aging population, a higher prevalence of conditions such as cataracts and age-related macular degeneration, advancements in technology allowing for more effective and accessible treatments, and growing awareness leading to earlier detection and intervention. Retinoblastoma treatment is required for ophthalmic surgeries to address the presence of cancerous growths within the eye(s) and to prevent metastasis or recurrence while preserving vision and eye function. For instance, in October 2023, according to the Royal National Institute of Blind People (RNIB), a UK-based sight loss charity, eye care outpatient appointments in the UK reached over eight million in 2022, the highest for any specialty, and the number of people with sight loss, currently exceeding two million, is expected to double to over four million by 2050. Therefore, the increasing demand for ophthalmic treatment and surgeries is driving the growth of the retinoblastoma treatment industry.

Key Players In The Global Retinoblastoma Treatment Market

Major companies operating in the retinoblastoma treatment market are Johnson And Johnson Services Inc., F Hoffmann La Roche AG, Merck And Co Inc., Sanofi SA, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co Ltd, Icon Bioscience Inc., Ono Pharmaceutical Co Ltd, Nippon Shinyaku Co Ltd, Cadila Pharmaceuticals, Phio Pharmaceuticals Inc., Bayer AG, AstraZeneca Plc, Sun Pharmaceutical Industries Ltd

Global Retinoblastoma Treatment Market Trends and Insights

Major companies operating in the retinoblastoma treatment market are focusing on developing advanced oncolytic virotherapy to improve efficacy and preserve vision in pediatric patients. Oncolytic virotherapy leverages engineered viruses that selectively infect and destroy cancer cells while sparing healthy tissue, thereby enhancing treatment safety and reducing side effects. For instance, in July 2024, Theriva Biologics, a U.S.-based clinical-stage company, received Rare Pediatric Disease Designation from the FDA for its lead candidate VCN-01, a systemically administered, stroma-degrading oncolytic adenovirus. VCN-01 selectively replicates within tumor cells, degrades the surrounding stroma to improve chemotherapy delivery, and promotes immune activation against the tumor. In a Phase 1 investigator-sponsored trial in pediatric patients with refractory retinoblastoma, intravitreal dosing of VCN-01 showed a favorable safety profile and encouraging clinical outcomes.

What Are Latest Mergers And Acquisitions In The Retinoblastoma Treatment Market?

In May 2025, the International Society of Ocular Oncology (ISOO), a Switzerland-based organization focused on research, education, and global advocacy in ocular oncology, formed a strategic partnership with the International Society of Paediatric Oncology (SIOP) to strengthen coordinated efforts in advancing retinoblastoma care worldwide. With this partnership, both organizations aim to expand global access to high-quality retinoblastoma treatment, improve clinical outcomes through shared expertise, and harmonize care protocols across diverse healthcare systems. International Society of Paediatric Oncology (SIOP) is a Switzerland-based multidisciplinary organization.

Regional Outlook

North America was the largest region in the retinoblastoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Retinoblastoma Treatment Market?

The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Retinoblastoma Treatment Market Report 2026?

The retinoblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.